Bhag:
>> ALL THIS IS SIMPLY AN EXPRESSION OF AN OPINION. NO MORE.
EMOTIONAL LONGS ARE REQUESTED TO DISREGARD THIS IF YOU
DON'T AGREE. <<
Chuckle. Point well-taken.
3340..... I can confidently say that AGPH's interest in continuing the trial is genuine. We should all look forward, with enthusiasm, to the data and its contributions to our knowledge regarding the growth of primary tumors and their metastases.
The trials are blinded. What do participants in this thread want, magic? The preclinical and phase I data convinced AGPH, the FDA and at least one private investor (me) that 3340 was worth testing in expanded trials.
I get really p*ssed at some participants in this thread..... AGPH is struggling, with intense sincerity, to control certain cancers. We will see the data when the data is available. The concept.... finding something other than poisons that selectively work in cancer cells..... is sound.
Can we use BBIOY results as an indicator? That will again involve "opinion", but I lean toward "yes".
Does the fact that AGPH is working on a third-generation MMPI indicate a willingness to cannibalize 3340? Certainly, and we'd be stupid to ignore such, just as we'd be stupid to ignore efforts at (and comments from) Chiroscience.
Why the hell are some in this thread talking about the termination of 3340 trials before the data has been collected? Greed is making a few contributors to this thread look really, really silly.
Closing comment..... the tracking Oncology unit..... I no longer have an equity position in AGPH, as my straddle has expired and it has been awhile since I owned any shares. I therefore won't be voting. If I were, however, I'd vote yes and give management and myself more flexibility going forward.
Rick |
